Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival

Xiaoyun Liao, Paul Lochhead, Reiko Nishihara, Teppei Morikawa, Aya Kuchiba, Mai Yamauchi, Yu Imamura, Zhi Rong Qian, Yoshifumi Baba, Kaori Shima, Ruifang Sun, Katsuhiko Nosho, Jeffrey A. Meyerhardt, Edward Giovannucci, Charles S. Fuchs, Andrew T. Chan, Shuji Ogino

Research output: Contribution to journalArticle

571 Citations (Scopus)

Abstract

Regular use of aspirin after a diagnosis of colon cancer has been associated with a superior clinical outcome. Experimental evidence suggests that inhibition of prostaglandin-endoperoxide synthase 2 (PTGS2) (also known as cyclooxygenase-2) by aspirin down-regulates phosphatidylinositol 3-kinase (PI3K) signaling activity. We hypothesized that the effect of aspirin on survival and prognosis in patients with cancers characterized by mutated PIK3CA (the phosphatidylinositol-4,5-bisphosphonate 3-kinase, catalytic subunit alpha polypeptide gene) might differ from the effect among those with wild-type PIK3CA cancers.
Original languageEnglish
Pages (from-to)1596-1606
Number of pages11
JournalThe New England Journal of Medicine
Volume367
Issue number17
DOIs
Publication statusPublished - 25 Oct 2012

Fingerprint Dive into the research topics of 'Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival'. Together they form a unique fingerprint.

  • Cite this

    Liao, X., Lochhead, P., Nishihara, R., Morikawa, T., Kuchiba, A., Yamauchi, M., Imamura, Y., Qian, Z. R., Baba, Y., Shima, K., Sun, R., Nosho, K., Meyerhardt, J. A., Giovannucci, E., Fuchs, C. S., Chan, A. T., & Ogino, S. (2012). Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. The New England Journal of Medicine, 367(17), 1596-1606. https://doi.org/10.1056/NEJMoa1207756